@synartro.com
Synartro is a research and development company
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Synartro is a Swedish life science company focused on developing novel treatments for osteoarthritis (OA). They specialize in local injection therapies that provide superior and sustained efficacy without systemic side-effects. Synartro achieves this by combining their patented hyaluronan-based drug delivery platform with existing proven drugs.
Their lead program, SYN321, is an intraarticular injection containing diclofenac and hyaluronan, specifically designed for knee OA. Unlike other treatments, SYN321 requires a significantly lower dose for desired efficacy while reducing side effects and providing prolonged pain relief. It also has disease-modifying potential, which could slow down or even halt the progression of the disease.
Synartro's innovative drug delivery technology enables a sustained release of the treatment, making it a beneficial option for other indications with systemic safety concerns. They are currently preparing for a first-in-human trial to assess safety and exploratory efficacy. With a strong focus on improving the lives of patients, Synartro aims to bring active life back to those suffering from OA.
Their patented technology, favorable safety profile in preclinical trials, and potential for long-term pain relief make SYN321 a promising candidate for second-line treatment in knee OA
Company Type
Privately Held
Company Size
2-10
Year Founded
2011
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories